“…These include, for example, a defect in the recognition of target cells with a relationship between HLA antigen expression and tumour cell performance (Stern et al, 1980;Karre et al, 1986;Powel et al, 1987;Rodger et al, 1988;Alonso et al, 1989;Ljnggren & Karre, 1990;Solana et al, 1990b;Peiia et al, 1990a,b); a resistance of target cells to lytic factors such as TNF or NKCF produced by immunocompetent cells (Roozemond et al, 1987); or an inhibited NK activity owing to tumour suppressor factors or peptides such as prostaglandin E2 and NK-RIF (Harris et al, 1987;Serrano et al, 1989Serrano et al, , 1990Solana et al, 1990a). However, the exact mechanisms by which NK cells interact with target cells remains unclear.…”